U.S Venture Partners (Menlo Park, CA)
With a long tenure in venture capital, Philip M. Young has had the pleasure of working with many entrepreneurs. In fact, he's recruited a number of USVP's partners from the ranks of entrepreneurs over the years, most recently Casey Tansey. Whether it's helping a serial entrepreneur scout out his next company, or helping portfolio companies recruit the best possible management team, Phil enjoys the role of coach and mentor.
Prior to joining USVP in 1990, Phil spent four years with Concord Partners, Dillon Read's venture capital operation in Palo Alto. With a specialty in the medical device industry, Phil has watched the evolution of new methodologies, such as the emergence of minimally-invasive treatments, into increasingly diverse and pervasive applications. Phil's investment interests aren't confined to medical devices and biotechnology, however. Recently he's been active in online advertising, a more than $10 billion industry growing at nearly 30 percent a year.
Phil arrived at USVP with extensive operating experience. He was President and CEO of Oximetrix, a manufacturer of critical care instruments and disposables, where he spent eight years growing the privately-held venture-backed company from $1 million in revenues to nearly $50 million. Prior to Oximetrix, Phil spent six years at New Court Securities in venture capital and corporate finance, two years as a management consultant with McKinsey & Co., and six years on Admiral Rickover's project management staff at the Atomic Energy Commission.
He serves on the Board of Trustees of Cornell University and as Chairman of the Board of eCornell, the university's online distance learning subsidiary. Phil enjoys photography, cooking and spending time with his wife in the South of France. He has two daughters and two grandchildren.
Phil earned a BME from Cornell University with High Distinction, an MS in Engineering Physics from George Washington University, and an MBA with High Distinction from Harvard University, where he was a Baker Scholar.
He has represented USVP on the boards of Aerogen, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, FemRx, Penederm, 3Dfx Interactive, Vical and Xoma â€“ all of which became public companies. Currently he sits on the boards of Zoran, a public company, and privately-held Aptus Endosystems, Bayhill Therapeutics, Caspian Networks, Claria, Dotomi, RelayHealth, Synarc, St. Francis Medical and Timi3 Systems.